logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
T

Thomas Decaens

univ. grenoble alpes
H指数:44
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer

Netrin1阻断减轻胰腺癌对化疗的耐药性

Nature
IF48.5
2026-04-220
OAAI
Gael Roth; Pascal Artru; Olivier Bouche; Nicolas Williet; Julien Ghelfi; Anthony Turpin; Astrid Lievre; Jean-Frédéric Blanc; Camille Evrard; Jean-Baptiste Bachet; Pauline Parent; Marc Manceau; Matthieu Roustit; Anna Borowik; Victoire Granger; Aurélie Durand; Christelle d’Engremont; Edouard Girard; Mircea Chirica; Nicolas Braissand; Nicolas Rama; Eugénie Modolo; Hector Hernandez-Vargas; Elise Georges; Jean-Yves Scoazec; Jerome Cros; Sébastien Hazard; Benjamin Ducarouge; Thomas Decaens; Agnès Bernet; Patrick Mehlen
A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer)

CheckMate 9DW研究的通俗总结：纳武利尤单抗联合伊匹木单抗治疗不可切除的肝细胞癌（晚期肝癌）

Future Oncology
IF2.6
2026-04-140
PRE
Thomas Yau; Peter R Galle; Thomas Decaens; Bruno Sangro; Shukui Qin; Leonardo G da Fonseca; Hatim Karachiwala; Jean-Frederic Blanc; Joong-Won Park; Edward Gane; Matthias Pinter; Ana Matilla Peña; Masafumi Ikeda; David Tai; Armando Santoro; Gonzalo Pizarro; Chang-Fang Chiu; Michael Schenker; Aiwu He; Hong Jae Chon; Joanna Wojcik-Tomaszewska; Gontran Verset; Qi Qi Wang; Caitlyn Stromko; Jaclyn Neely; Prianka Singh; Maria Jesus Jimenez Exposito; Masatoshi Kudo
Hepatitis D Virus Seroconversion Rate Among People With Chronic Hepatitis B Virus Infection in France and The Gambia (Inci-D)

法国和冈比亚慢性乙型肝炎病毒感染者中丁型肝炎病毒的血清转化率（Inci-D）

Open Forum Infectious Diseases
IF3.8
2026-01-011
PRE
Ingiliz, Patrick; Quang, Erwan Vo; Ndow, Gibril; Lemoine, Maud; Ceesay, Amie; Drammeh, Sainabou; Hilleret, Marie-Noelle; Bordy, Laure; Decaens, Thomas; Mazialivoua, Anne-Laure; Shimakava, Yusuke; Touray, Alhagie B.; Pawlotsky, Jean-Michel; Chemin, Isabelle; Chevaliez, Stephane; Leroy, Vincent
Corrigendum to: “Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study” [J Hepatol (2024) 278-288]

勘误：针对“接受桥接治疗的患者延迟肝移植策略评估：DELTA-HCC研究” [J Hepatol (2024) 278-288]

Journal of Hepatology
IF33
2025-10-270
OAAI
Catherine Lamarque; Lauriane Segaux; Philippe Bachellier; Benjamin Buchard; Faiza Chermak; Filomena Conti; Thomas Decaens; Sébastien Dharancy; Vincent Di Martino; Jérôme Dumortier; Claire Francoz-Caudron; Jean Gugenheim; Jean Hardwigsen; Fabrice Muscari; Sylvie Radenne; Ephrem Salamé; Thomas Uguen; José Ursic-Bedoya; Corinne Antoine; Aurélie Deshayes; Christian Jacquelinet; Pierre-André Natella; Vincent Leroy; Daniel Cherqui; Nadia Oubaya; Christophe Duvoux
Real-World Outcomes of Atezolizumab–Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort

阿特珠单抗–贝伐珠单抗在肝细胞癌中的真实世界结局：法国前瞻性CHIEF队列研究

Liver International
IF5.2
2025-09-040
OAAI
Manon Allaire; Elhadji Malick Thiam; Guiliana Amaddeo; Mohamed Bouattour; Julien Edeline; Bleuenn Brusset; Marianne Ziol; Philippe Merle; Jean Frédéric Blanc; Thomas Uguen; Nathalie Ganne; Stéphane Cattan; Ghassan Riachi; Véronique Loustaud-Ratti; Thomas Decaens; Christine Silvain; Jean Marie Peron; Aurore Baron; Georges Philippe Pageaux; Frédéric Oberti; Rodolphe Anty; Alina Pascale; Sylvain Manfredi; Marc Bourliere; Jean Baptiste Nousbaum; Alexandra Heurgue; Isabelle Ollivier-Hourmand; Marie Lequoy; Jean Pierre Bronowicki; Anne Laure Villing; Gerard Ducournau; Olivier Ganry; Charlotte Costentin; Eric Nguyen-Khac
A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data

一项多中心国家II期临床试验，评估Tislelizumab单药治疗Child-Pugh B级和ALBI 1级或2级肝功能评分的肝细胞癌患者的疗效：UCGI 41 HESTIA试验设计与初步安全性数据

Digestive and Liver Disease
IF3.8
2025-08-050
PRE
Héloïse Bourien; Xavier Adhoute; Boris Campillo-Gimenez; Mohamed Bouattour; Eric Assenat; Pierre Nahon; Simon Launay; Frédéric Oberti; Antonio Saviano; Thomas Decaens; Philippe Merle; Alexandre Harlé; Thierry Lecomte; David Ternant; Laure Monard; Veronica Pezzella; Jean-Frédéric Blanc; Julien Edeline
Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis

非侵入性检测动态在指导肝硬化患者HCV治愈后HCC监测决策中的价值

Journal of Hepatology
IF33
2025-02-260
PRE
Pierre Nahon; Clovis Lusivika-Nzinga; Philippe Merle; Fabien Zoulim; Thomas Decaens; Nathalie Ganne-Carrié; Georges-Philippe Pageaux; Vincent Leroy; Laurent Alric; Jean-Pierre Bronowicki; Marc Bourlière; Jérôme Gournay; Albert Tran; Stanislas Pol; Philippe Mathurin; Véronique Loustaud-Ratti; Sophie Métivier; Victor De Ledinghen; Armand Abergel; Dominique Thabut; Louis D’Alteroche; Mohammed Bouattour; Tarik Asselah; Denis Ouzan; Paul Cales; Olivier Chazouillères; Moana Gelu-Simeon; Dominique Roulot; Jérôme Boursier; Carole Cagnot; Sonia Tamazirt; Alina Pascale; Samuel Nilusmas; Maïté Lewin; Marianne Ziol; Fabrice Carrat; Jean-Charles Duclos-Vallée
Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC)

EMERALD-1研究中基线肿瘤负荷对结局的影响：一项关于度伐利尤单抗（D）±贝伐珠单抗（B）联合经动脉化疗栓塞（TACE）在栓塞适应症的不可切除肝细胞癌（uHCC）中的III期研究

ANNALS OF ONCOLOGY
IF65.4
2024-12-011
PRE
Kudo, M.; Lencioni, R.; Erinjeri, J.; Chan, S. L.; Qin, S.; Ren, Z.; Arai, Y.; Heo, J.; Breder, V. V.; Bouattour, M.; Dayyani, F.; Yoon, J-H.; Chiu, C-F.; Suttichaimongkol, T.; Decaens, T.; Griffin, R.; Morgan, C.; Ali, S. K.; Balaji, K.; Sangro, B.
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW Asian subgroup analysis

纳武利尤单抗（NIVO）联合伊匹木单抗（IPI）与乐伐替尼（LEN）或索拉非尼（SOR）作为不可切除肝细胞癌（uHCC）的一线（1L）治疗方案：CheckMate 9DW亚洲亚组分析

ANNALS OF ONCOLOGY
IF65.4
2024-12-011
PRE
Yau, T.; Galle, P. R.; Decaens, T.; Sangro, B.; Qin, S.; Park, J-W.; Ikeda, M.; Tai, D. W. M.; Chiu, C-F.; Chon, H. J.; Kang, Y-K.; Hiraoka, A.; Huang, Y-H.; Lee, T-Y.; Numata, K.; Yamashita, T.; Ogata, T.; Hreiki, J.; Lu, Y.; Kudo, M.
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW

纳武利尤单抗（NIVO）联合伊匹木单抗（IPI）对比仑伐替尼（LEN）或索拉非尼（SOR）作为不可切除肝细胞癌（uHCC）的一线（1L）治疗方案：CheckMate 9DW研究的扩展分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-012
PRE
Decaens, T.; Yau, T.; Kudo, M.; Sangro, B.; Qin, S.; Da Fonseca, L.; Karachiwala, H.; Park, J-W.; Gane, E.; Pinter, M.; Tai, D. W. M.; Santoro, A.; Pizarro, G.; Chiu, C-F.; Schenker, M.; He, A. R.; Wang, Q.; Ogata, T.; Hreiki, J.; Galle, P. R.
Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)

EMERALD-1研究中的基线肿瘤负荷分层结果：一项评估度伐利尤单抗（D）联合或不联合贝伐珠单抗（B）与经动脉化疗栓塞术（TACE）治疗栓塞术适用型不可切除性肝细胞癌（uHCC）患者的III期、随机、安慰剂（PBO）对照研究

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Kudo, M.; Lencioni, R.; Erinjeri, J. P.; Chan, S. L.; Qin, S.; Ren, Z.; Arai, Y.; Heo, J.; Breder, V.; Bouattour, M.; Dayyani, F.; Yoon, J-H.; Chiu, C-F.; Suttichaimongkol, T.; Decaens, T.; Griffin, R.; Morgan, C.; Ali, S. K.; Balaji, K.; Sangro, B.

研究方向

暂未获取到该数据
A
Alexis Laurent
H 指数:88论文数:465被引数:3.0万
C
Christophe Duvoux
H 指数:56论文数:276被引数:1.2万
Z
Zuzana Macek Jílková
H 指数:27论文数:117被引数:3,610
D
Daniel Cherqui
H 指数:92论文数:744被引数:3.3万
C
Charlotte Costentin
H 指数:32论文数:155被引数:5,653
A
Alain Luciani
H 指数:54论文数:381被引数:1.4万
S
Sébastien Dharancy
H 指数:55论文数:395被引数:1.5万
G
Gaël S. Roth
H 指数:21论文数:143被引数:1,231
P
Patrice N. Marche
H 指数:47论文数:323被引数:8,957
F
Françoise Roudot‐Thoraval
H 指数:74论文数:541被引数:2.1万